PD-1/PD-L1

  • 阻害剤の選択性比較
  • 溶解度
カタログ番号 製品カタログ 溶解度(25°C)
DMSO アルコール
S8158 PD-1/PD-L1 Inhibitor 3 100 mg/mL -1 mg/mL -1 mg/mL
S7912 PD-1/PD-L1 inhibitor 2 <1 mg/mL 83 mg/mL 83 mg/mL
S8549 AUNP-12 100 mg/mL -1 mg/mL -1 mg/mL
S7911 PD-1/PD-L1 inhibitor 1 95 mg/mL 95 mg/mL 95 mg/mL
製品コード 製品説明 文献中の使用例 お客様のフィードバック
S8158

PD-1/PD-L1 Inhibitor 3

PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)は一種のPD-1/PD-L1相互作用阻害剤です。

S7912

PD-1/PD-L1 inhibitor 2

PD-1/PD-L1 inhibitor 2は一種のPD-1/PD-L1相互作用阻害剤です。

S8549

AUNP-12

S7911

PD-1/PD-L1 inhibitor 1

PD-1/PD-L1 inhibitor 1は一種のPD-1/PD-L1相互作用阻害剤です。

A2002

Nivolumab

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities.

A2004

Atezolizumab

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1.

A2005

Pembrolizumab

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities.

製品コード 製品説明 文献中の使用例 お客様のフィードバック
S8158

PD-1/PD-L1 Inhibitor 3

PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)は一種のPD-1/PD-L1相互作用阻害剤です。

S7912

PD-1/PD-L1 inhibitor 2

PD-1/PD-L1 inhibitor 2は一種のPD-1/PD-L1相互作用阻害剤です。

S8549

AUNP-12

S7911

PD-1/PD-L1 inhibitor 1

PD-1/PD-L1 inhibitor 1は一種のPD-1/PD-L1相互作用阻害剤です。

A2002

Nivolumab

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities.

A2004

Atezolizumab

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1.

A2005

Pembrolizumab

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities.

Tags: PD-1/PD-L1 inhibition | PD-1/PD-L1 cancer | PD-1/PD-L1 signaling pathway | PD-1/PD-L1 assay | PD-1/PD-L1 inhibitor cancer | PD-1/PD-L1 inhibitor review